

SARS-CoV-2 variants neutralisation studies to predict vaccines effectiveness

Oleg Volkov

Xitific LTD, UK

Abstract

Response to emerging SARS-CoV-2 variants could be amplified by correlates of immune protection. They would allow predicting vaccine effectiveness from in-vitro data, without months-long clinical trials and observational studies. Despite intensive research and an acute need, few correlates frameworks have been established for SARS-CoV-2 vaccines.

This talk introduces such a framework which utilises neutralisation studies with SARS-CoV-2 variants. We consider how it could boost established vaccines and accelerate new vaccine development. We also consider study designs for improved predictions and vaccination policies.